A study on 3.7 million individuals at the New York University School of Medicine shows 18 percent lower risk of peripheral artery disease (PAD) in individuals with the consumption of at least three pieces of fruit and vegetables per day when compared with those individuals who are consuming less.
The study shows 6.3 percent of the population was affected by the peripheral artery disease (PAD) and 29.2 percent of people are consuming at least three servings of fruit and vegetables. This study shows the significance of consuming fruit and vegetables in lowering the risk associated with the peripheral artery disease (PAD). This study also confirms a dismally low consumption of the fruit and vegetables among citizens. The study found that the number of people consuming at least three servings of fruit and vegetables is the highest in the older white women and the lowest in the younger black men.
Peripheral artery disease (PAD) can restrict the flow of oxygen-rich blood to the muscles in the leg and causes difficulties and pains when a patient is standing or walking. Author of the study was Dr. Jeffrey Berger, an associate professor of medicine and surgery, the New York University School of Medicine. The co-author of the study was Sean Heffron, the New York University School of Medicine. The study was published in the American Heart Association journal Arteriosclerosis, Thrombosis and Vascular Biology.
Israeli scientists from Sheba Medical Center and the Ben-Gurion University of the Negev have developed a new and innovative treatment for atherosclerosis and to fight against stroke and heart diseases. Researchers have developed a biomedical nano-polymer therapy to fight against stroke and heart diseases, which is a better treatment option compared to the treatment with statins.
The new treatment option can lower the plaque and inflammation in the arteries that transport the blood rich with the oxygen and nutrients to organs, tissues and cells. The new therapy can prevent the future development of plaque and inflammation. Plaque formation in the arteries is a risk factor for diseases such as arterial thrombosis, myocardial infarction, ischemia and stroke. The advantages of the biomedical nano-polymer therapy are.
The polymer therapy (patented) is in the preclinical stage. Experiments with the mice models are positive and there was a remarkable improvement in the health of the arteries. The thickness of the arteries was lowered and there was less inflammation. Scientists say the new therapy can help a patient in lowering the health risks associated with the old age such as high blood pressure (hypertension. BP), high cholesterol levels and high blood sugar (glucose) levels (type 2 diabetes).
Dr. Ora Horovitz, senior vice president of business development at the BGN Technologies, the technology transfer division of the Ben-Gurion University of the Negev, says they are looking for a pharmaceutical company for the further development and marketing of the new therapy.
Researchers at the University of Adelaide have developed a new type 2 diabetes (T2D) drug that can work effectively in lowering the blood sugar (glucose) levels with a lower number of insulin injections. The new drug can help the patient in lowering the blood sugar (glucose) levels. The new drug act at the molecular level by activating (fully or partially) the PPARgamma protein receptor. Tissues of the body contain the PPARgamma protein receptor.
The drug increases the insulin levels and changes the metabolism of the fat and sugar. The original version of the drug (INT131) is currently under clinical trials in the United States. The latest version of the drug was improved even further for the treatment of type 2 diabetes. Lead researcher of the study was Dr. John B. Bruning, Senior Lecturer, The University of Adelaide, Australia.
The Diabetes News Chronicle does not provide medical advice, diagnosis or treatment. Information in Diabetes News Chronicle is to support and not to replace medical advice given by the surgeon or physician or doctor. Published article is not a medical advice by the OWNER of the "Diabetes News Chronicle" website or by the AUTHOR of the article.
Published by Jammi Vasista, Chennai, India.